Gene Biotherapeutics Inc. (CRXM)
Stock Price: $0.0540 USD
0.0040 (8.00%)
Updated May 7, 2021 3:56 PM EDT - Market closed
| Market Cap | 2.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 866,675 |
| Shares Out | 14.49M |
| EPS (ttm) | 0.06 |
| PE Ratio | 0.90 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $0.0540 |
| Previous Close | $0.0500 |
| Change ($) | 0.0040 |
| Change (%) | 8.00% |
| Day's Open | 0.0540 |
| Day's Range | 0.0531 - 0.0570 |
| Day's Volume | 810,888 |
| 52-Week Range | 0.0204 - 0.1500 |
News
There are no news available yet.
About CRXM
Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology p... [Read more...]
| Industry Biotechnology | Founded 2003 |
| CEO Christopher Reinhard | Employees 4 |
| Stock Exchange OTCMKTS | Ticker Symbol CRXM |